Lin BioScience, Inc.
6696
Kedudukan dalam Saham
#3771
Lin BioScience, Inc. is an innovative biopharmaceutical company focused on... Lin BioScience, Inc. is an innovative biopharmaceutical company focused on developing novel therapies across oncology, ophthalmology, and metabolic diseases. Its robust pipeline includes LBS-008, an orally administered treatment currently in Phase 3 clinical trials for adolescent Stargardt disease (STGD1) and Phase 2/3 trials for dry age-related macular degeneration (Dry AMD), both aimed at evaluating its safety and effectiveness. Other key candidates are LBS-007, a natural non-ATP CDC7 inhibitor designed to combat various cancers; LBS-002, an anti-tubulin compound targeting primary and metastatic brain tumors; and LBS-009, an oral medication for non-alcoholic fatty liver disease and Type 2 diabetes. The company is headquartered in Taipei, Taiwan.
Harga Saham
$5.34
Modal Pasaran
$4.43B
Perubahan (1 hari)
3.07%
Perubahan (1 tahun)
-39.48%
Negara
TW
Perdagangan Lin BioScience, Inc. (6696)
Kategori
Healthcare
Sejarah hasil dividen untuk Lin BioScience, Inc. (6696)
Hasil dividen (TTM) bagi Lin BioScience, Inc. (simbol saham: 6696) pada 2026 adalah: 0
Purata hasil dividen 5 tahun terakhir: 0.00%
Purata hasil dividen 5 tahun terakhir: 0.00%
Sejarah hasil dividen untuk Lin BioScience, Inc. (6696) dari 2026 hingga 2026
Hasil dividen pada akhir setiap tahun (TTM)
| Tahun | Hasil Dividen | Ubah |
|---|---|---|
| Tidak cukup data untuk tarikh yang disediakan. | ||
Hasil dividen (TTM) untuk syarikat serupa atau pesaing
| Syarikat | Hasil Dividen | Negara |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
